According to a recent LinkedIn post from SpinaFX Medical Inc, the company attracted strong interest in a workshop at the ASSR 2026 meeting in New Orleans focused on image-guided intra-discal oxygen ozone injection for contained herniated discs. The session reportedly allowed participants to practice C-arm guided needle placement and review clinical evidence, patient selection, and follow-up.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The post also notes discussion of SpinaFX’s planned pivotal clinical trial, indicating that the company may be progressing toward more robust clinical validation of its minimally invasive back pain therapy. For investors, this suggests advancing clinical and physician-engagement efforts that could, if successful, support future regulatory milestones, adoption by interventional specialists, and longer-term commercialization prospects in spine-focused medtech markets.